We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News

Executive Summary

COLUMBIA LABS CRINONE NDA APPROVAL ANTICIPATED IN SECOND QUARTER, Chairman William Bologna told investors Jan. 23 at the American Stock Exchange Health Care Conference in New York. "This product has been given priority rating at the FDA and we have a six-month review" schedule, he said. "We expect approval in the U.S. next quarter." The NDA for Crinone (progesterone) for use in assisted reproductive technology procedures was filed on Nov. 13 and subsequently granted priority review status. The user fee deadline is May 13.